Testing Nerandomilast for Scarring Lung Disease
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can provide informed consent
- You have been diagnosed with fibrosing interstitial lung disease (but not the specific type called IPF) within the last 3 years
- Your CT scan shows lung scarring affecting at least 10% of your lungs
- Your lung function test (FVC) is at least 45% of normal, and your oxygen transfer capacity (DLCO) is at least 25% of normal
- If you take immune-suppressing medications for another condition, you must have been on a stable dose for at least 12 weeks
- You have not previously taken nerandomilast, nintedanib, or pirfenidone
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Hear when a new Interstitial Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.